Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Investing Activities (2020 - 2025)

Bolt Biotherapeutics' Cash from Investing Activities history spans 6 years, with the latest figure at $17.9 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 4.35% year-over-year to $17.9 million; the TTM value through Sep 2025 reached $55.5 million, down 9.31%, while the annual FY2024 figure was $57.6 million, 18.95% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was $17.9 million at Bolt Biotherapeutics, up from $10.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $40.8 million in Q1 2022 and bottomed at -$190.5 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is $13.6 million (2023), against an average of -$131421.1.
  • The largest annual shift saw Cash from Investing Activities plummeted 1300.07% in 2021 before it skyrocketed 1664.52% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $21.0 million in 2021, then decreased by 21.86% to $16.4 million in 2022, then decreased by 3.81% to $15.8 million in 2023, then dropped by 22.63% to $12.2 million in 2024, then surged by 46.21% to $17.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Cash from Investing Activities are $17.9 million (Q3 2025), $10.8 million (Q2 2025), and $14.6 million (Q1 2025).